Patients coinfected with hepatitis C virus (HCV) and HIV undergoing liver transplantation (LT) are at risk of early, aggressive HCV recurrence. This study investigates the use of frequent protocol-driven biopsies to identify HCV recurrence post LT in coinfected patients. Five consecutive HIV/HCV-coinfected patients underwent LT. Liver biopsies were obtained post LT at 1 hour; days 7, 120, and 365; then annually; and as clinically indicated. Stage 2 (Ishak) or higher fibrosis occurred in 4 of the 5 patients by 60, 120, 270, and 365 days. Two patients died of HCV recurrence and liver failure at 6 and 35 months post LT. Three patients survived more than 4 years after LT, 2 having sustained virologic responses to anti-HCV treatment. Another has histologic recurrence not responding to treatment. Hepatitis C virus recurrence can be rapid and aggressive after LT in HIV-coinfected patients. Serial biopsies identify recurrence early, allowing for prompt initiation of treatment.
Palella JF, Delaney KM, Mooman ACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. 1998;338(13):853.
2.
Anderson R.Double Trouble: Hepatitis and HIV Coinfections Require Special Attention (Data from CHORUS Database). LifeGuide A&U2000 ; 59.
3.
Alter MJ, Kruszon-Moran D., Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med. 1999 ;341(8):556-562.
4.
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clini Infect Dis. 2002;34(6):831-837.
5.
Troisi C., Hollinger FB, Hoots W., et al. A multicenter study of viral hepatitis in a United States hemophiliac population. Blood. 1993;81(2):412-418.
6.
Berenguer M. , Wright TLHepatitis C and liver transplantation. Gut. 1999;45(2):159.
7.
Everhart JE, Wei Y., Eng H., et al. Recurrent and new hepatitis C virus infection after liver transplantation [published erratum appears in Hepatology 1999 Oct;30(4):1110]. Hepatology. 1999;29(4):1220-1226.
8.
Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJIncreasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84(4):1020-1023.
9.
Norris S., Taylor C., Muiesan P., et al. Outcomes of liver transplantation in HIV-infection individuals: the impact of HCV and HBV infection. Liver Transpl. 2004;10(10):1271-1278.
10.
Neff GW, Bonham A., Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9(3):239-247.
11.
Castells L. , Escartin A., Bilbao I., et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation. 2007;83(3):354-358.
12.
de Vera ME, Dvorchik I., Tom K., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant . 2006;6(12):2983-2993.
13.
Prachalias AA, Pozniak A., Taylor C., et al. Liver transplantation in adults coinfected with HIV. Transplantation. 2001;72(10): 1684-1688.
14.
Schvarcz R. , Soderdahl G.Successful hepatitis C virus treatment in patients coinfected with HIV after liver transplantation. Transplantation. 2005;79(7):853.
15.
Ishak K., Baptista A., Bianchi L., et al. Histologic grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699.
16.
Ormonde DG, de Boer WB, Kierath A., et al. Banff criteria for grading liver allograft rejection: utility in clinical practice. Liver Trans Surg. 1999 ;5(4):261-268.
17.
Poynard T., Bedossa P., Opolon P.Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet . 1997; 349(9055):825-832.
18.
Kenny-Walsh E.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group . N Engl J Med. 1999;340(16):1228-1233.
19.
Mohsen AH, Easterbrook PJ, Taylor C., et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003; 52(7):1035-1040.
20.
Poynard T., Mathurin P., Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases . J Hepatol. 2003;38(3): 257-265.
21.
Benhamou Y. , Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999; 30(4):1054-1058.
22.
Graham CS, Baden LR, Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-569.
23.
Ghany MG, Leissinger C., Lagier R., Sanchez-Pescador R., Lok ASEffect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci. 1996; 41(6):1265-1272.
24.
Sherman KE, O’Brien J., Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol. 1993; 31(10):2679-2682.
25.
Thomas DL, Shih JW, Alter HJ, Vlahov D., Cohn S., Hoover DR, Cheung L., Nelson KEEffect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996;174(4):690-695.
26.
Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJIncreasing hepatitis C virus RNA levels in hemophiliacs: relationship of human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84(4): 1020-1023.
27.
Beld M., Penning M., Lukashov V., et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology. 1998;244(2): 504-512.
28.
Chung RT, Anderson J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351(5):451-459.
29.
Torriani FJ, Rodriguez-Torres M., Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
30.
Perronne C., Carrat F., Bani-Sadr F., et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of peglyated interferon-alfa-2b plus ribavirin vs. interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV coinfected patients [abstract 686]. In: Program and Abstracts of the 11 th Conference on Retroviruses and Opportunistic Infections (San Francisco). 8-11 Feb 2004. Abstract 177LB. Alexandra, VA : Foundation for Retrovirology and Human Health; 2004: 545.
31.
Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839-2848.
32.
Ferenci P.Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004;24(suppl 2):25-31.
33.
Laguno M., Murillas J., Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS. 2004;18(13): F27-F36.
34.
Fauci AS, Schnittman SM, Poli G., Koenig S., Pantaleo G.Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection . Ann Intern Med. 1991;114(8):678-693.
35.
Ragni MV, Belle SHImpact of human immunodeficiency virus infection on progression of end-stage liver disease in individuals with hemophilia and hepatitis C virus infection . J Infect Dis. 2001;183(7):112-115.
36.
Matthews GV , Dore GJHIV and hepatitis C confection. J Gastroenterol Hepatol. 2008;23(7 Pt 1):1000-1008.
